Zalavras Charalampos G, Vartholomatos George, Dokou Eleni, Malizos Konstantinos N
Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, LAC + USC Medical Center, Los Angeles, CA 90033, USA.
Clin Orthop Relat Res. 2004 May(422):251-5.
Intravascular coagulation is considered a major pathogenetic mechanism for nontraumatic osteonecrosis. The aim of our study was to evaluate the association of thrombophilic factor V G1691A mutation (factor V Leiden) and G20210A prothrombin mutation with the disease. Mutation presence was investigated by polymerase chain reaction techniques in a study population of 72 adult Caucasian patients with osteonecrosis of the femoral head and 300 healthy Caucasian control subjects. The disease was considered idiopathic in 23 patients and secondary in 49. The factor V Leiden mutation was present in 18% of patients, compared with 4.6% of control subjects, resulting in a statistically significant odds ratio of 4.5. The prothrombin mutation was not significantly increased in the idiopathic osteonecrosis subgroup (8.7% versus 2.6%) with an odds ratio of 3.5. Overall, either of these coagulation disorders was present in 22.2% of patients and in 7.3% of control subjects resulting in a significant odds ratio of 3.6. Factor V Leiden, a genetic risk factor for venous thrombosis, is associated with nontraumatic osteonecrosis of the femoral head, supporting the hypothesis that intravascular coagulation is a major pathogenetic mechanism of the disease.
血管内凝血被认为是非创伤性骨坏死的主要发病机制。我们研究的目的是评估血栓形成倾向因子V G1691A突变(因子V莱顿突变)和凝血酶原G20210A突变与该疾病的关联。通过聚合酶链反应技术对72例成年白种人股骨头坏死患者和300例健康白种人对照者的研究群体进行突变检测。该疾病在23例患者中被认为是特发性的,在49例中是继发性的。因子V莱顿突变在18%的患者中存在,而对照者中为4.6%,导致统计学上显著的优势比为4.5。在特发性骨坏死亚组中,凝血酶原突变没有显著增加(8.7%对2.6%),优势比为3.5。总体而言,这些凝血障碍中的任何一种在22.2%的患者和7.3%的对照者中存在,导致显著的优势比为3.6。因子V莱顿突变是静脉血栓形成的遗传危险因素,与股骨头非创伤性骨坏死相关,支持血管内凝血是该疾病主要发病机制的假说。